Dataset Information

Quantification of Peptide 2 (RLLWENGNL) concentration in the mouse plasma

ABSTRACT: Diabetes mellitus (DM) causes the change in the components of the plasma, which may induce tissue and organ injuries, including the heart and kidney. In the diabetic model db/db mice, intravenous injection of purified dipeptidyl peptidase III (DPPIII) attenuated the heart and kidney damages provoked by DM without alteration in blood glucose level. This led us to hypothesize that there might be peptide(s) that are involved in the progression of the DM-mediated damages and are cleaved by DPPIII. To explore the peptides, the whole peptidomics analysis (shotgun peptidomics) was conducted using tandem mass spectrometry, in which peptides derived from the plasma of PBS-infused C57BL/6 mice, PBS-infused db/db mice, and DPPIII-treated db/db mice were compared. The raw mass spectrometry data were deposited to the ProteomeXchange with the dataset identifier PXD025440. Together with the mass spectrometry analysis and other experiments, we identified a peptide named Peptide 2 (AA sequence: RLLWENGNL) as a substrate of DPPIII. Peptide 2 is a part of C3f (53% identical), and C3f can act as an anaphylatoxin like C3a. To quantify the amount in plasma derived from the plasma of PBS-infused C57BL/6 mice, PBS-infused db/db mice, and DPPIII-treated db/db mice, selected reaction monitoring (SRM) assay was performed. All of the chromatograms and quantified data obtained by SRM from the three mouse groups were shown in the Analyst formated and PDF files.

INSTRUMENT(S): Q TRAP

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Blood Plasma

SUBMITTER: Akio Shimizu

LAB HEAD: Hisakazu Ogita

PROVIDER: PXD025469 | Pride | 2022-02-17

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	Mouse_plasma_assay-2nd.wiff	Wiff
	Mouse_plasma_assay-2nd.wiff.scan	Wiff
	Mouse_plasma_assay.wiff	Wiff
	Mouse_plasma_assay.wiff.scan	Wiff
	shiga-1.pdf	Pdf

Items per page:

1 - 5 of 6

Publications

Cardio- and reno-protective effects of dipeptidyl peptidase III in diabetic mice.

Komeno Masahiro M Pang Xiaoling X Shimizu Akio A Molla Md Rasel MR Yasuda-Yamahara Mako M Kume Shinji S Rahman Nor Idayu A NIA Soh Joanne Ern Chi JEC Nguyen Le Kim Chi LKC Ahmat Amin Mohammad Khusni B MKB Kokami Nao N Sato Akira A Asano Yoshihiro Y Maegawa Hiroshi H Ogita Hisakazu H

The Journal of biological chemistry 20210101

Diabetes mellitus (DM) causes injury to tissues and organs, including to the heart and kidney, resulting in increased morbidity and mortality. Thus, novel potential therapeutics are continuously required to minimize DM-related organ damage. We have previously shown that dipeptidyl peptidase III (DPPIII) has beneficial roles in a hypertensive mouse model, but it is unknown whether DPPIII has any effects on DM. In this study, we found that intravenous administration of recombinant DPPIII in diabet ...[more]

PMID: 33971198

Similar Datasets

Project description:FGF21 is a novel secreted protein with robust anti-diabetic, anti-obesity, and anti-atherogenic activities in preclinical species. In the current study, we investigated the signal transduction pathways downstream of FGF21 following acute administration of the growth factor to mice. Focusing on adipose tissues, we identified FGF21-mediated downstream signaling events and target engagement biomarkers. Specifically, RNA profiling of adipose tissues and phosphoproteomic profiling of adipocytes, following FGF21 treatment revealed several specific changes in gene expression and post-translational modifications, specifically phosphorylation, in several relevant proteins. Affymetrix microarray analysis of white adipose tissues isolated from both C57BL/6 (fed either regular chow or HFD) and db/db mice identified over 150 robust potential RNA transcripts and over 50 potential secreted proteins that were changed greater than 1.5 fold by FGF21 acutely. Phosphoprofiling analysis identified over 130 phosphoproteins that were modulated greater than 1.5 fold by FGF21 in 3T3-L1 adipocytes. Bioinformatic analysis of the combined gene and phosphoprotein profiling data identified a number of known metabolic pathways such as glucose uptake, insulin receptor signaling, Erk/Mapk signaling cascades, and lipid metabolism. Moreover, a number of novel events with hitherto unknown links to FGF21 signaling were observed at both the transcription and protein phosphorylation levels following treatment. We conclude that such a combined "omics" approach can be used not only to identify robust biomarkers for novel therapeutics but can also enhance our understanding of downstream signaling pathways; in the example presented here, novel FGF21-mediated signaling events in adipose tissue have been revealed that warrant further investigation. Three mouse strains (C57BL6 on chow diet, C57BL6 on high fat diet, and db/db on chow diet) were treated with either vehicle, wild-type FGF21, or pegylated FGF21 acutely or for several days and three white adipose tissues (IWAT, EWAT, RPWAT) and brown adipose tissue (BAT) were profiled on custom Affymetrix microarrays. The primary goal was to identify robust and consistent acute target engagement biomarkers of FGF21 activation in white adipose tissues.

Project description:This track displays a chromatin state segmentation for each of nine human cell types (http://hgwdev.cse.ucsc.edu/cgi-bin/hgEncodeVocab?term=GM12878,H1-hESC,HepG2,HUVEC,HMEC,HSMM,K562,NHEK,NHLF). A common set of states across the cell types were learned by computationally integrating ChIP-seq data for nine factors plus input (http://hgwdev.cse.ucsc.edu/cgi-bin/hgEncodeVocab?term=CTCF,H3K4me1,H3K4me2,H3K4me3,H3K27ac,H3K9ac,H3K36me3,H4K20me1,H3K27me3,Input) using a Hidden Markov Model (HMM). In total, fifteen states were used to segment the genome, and these states were then grouped and colored to highlight predicted functional elements. For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf ChIP-seq data from the Broad Histone (http://hgwdev.cse.ucsc.edu/cgi-bin/hgTrackUi?db=hg18&g=wgEncodeBroadChipSeq) track was used to generate this track. Data for nine factors plus input (http://hgwdev.cse.ucsc.edu/cgi-bin/hgEncodeVocab?term=CTCF,H3K4me1,H3K4me2,H3K4me3,H3K27ac,H3K9ac,H3K36me3,H4K20me1,H3K27me3,Input) and nine cell types (http://hgwdev.cse.ucsc.edu/cgi-bin/hgEncodeVocab?term=GM12878,H1-hESC,HepG2,HUVEC,HMEC,HSMM,K562,NHEK,NHLF) was binarized separately at a 200 base pair resolution based on a Poisson background model. The chromatin states were learned from this binarized data using a multivariate Hidden Markov Model (HMM) that explicitly models the combinatorial patterns of observed modifications (Ernst and Kellis, 2010). To learn a common set of states across the nine cell types, first the genomes were concatenated across the cell types. For each of the nine cell types, each 200 base pair interval was then assigned to its most likely state under the model. Detailed information about the model parameters and state enrichments can be found in (Ernst et al, accepted). This is release 1 (Jun 2011) of this track, and it is based on the NCBI36/hg18 release of the Broad Histone (http://hgwdev.cse.ucsc.edu/cgi-bin/hgTrackUi?db=hg18&g=wgEncodeBroadChipSeq) track. This track has also been lifted over to GRCh37/hg19 (http://hgwdev.cse.ucsc.edu/cgi-bin/hgTrackUi?db=hg19&g=wgEncodeBroadHmm). It is anticipated that the HMM methods will be run on the newer GRCh37/hg19 Broad Histone (http://hgwdev.cse.ucsc.edu/cgi-bin/hgTrackUi?db=hg19&g=wgEncodeBroadHistone) data and will replace the lifted version.